Doxribtimine
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Management of patients with thymidine kinase 2 deficiency: where are we now?
Journal: Expert opinion on pharmacotherapy
Published: August 15, 2026
Clinical development in primary mitochondrial diseases at a translational inflection point: Lessons, mechanisms, and emerging therapeutic strategies.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: April 21, 2026
Is an emerging pharmacotherapeutic era for rare mitochondrial diseases here?
Journal: Cell metabolism
Published: April 18, 2026
Effect of Renal Impairment on the Pharmacokinetics and Safety of Doxecitine and Doxribtimine: A Single-Dose Phase 1 Study.
Journal: Clinical pharmacology in drug development
Published: October 07, 2025
Disease burden of untreated thymidine kinase 2 deficiency: insights from a large patient dataset.
Journal: Brain communications
Published: September 15, 2025
Efficacy and safety of pyrimidine nucleos(t)ide therapy in thymidine kinase 2 deficiency.
Journal: Brain communications
Published: September 15, 2025
Late-onset TK2 deficiency in adults: Long-term clinical outcomes of deoxynucleoside therapy.
Journal: Mitochondrion
Published: July 23, 2025
Doxecitine and doxribtimine treatment in an adult patient with thymidine kinase 2 deficiency.
Journal: Molecular genetics and metabolism
Published: March 13, 2025
Pharmacokinetics and Safety of a 1:1 Mixture of Doxecitine and Doxribtimine: Open-label Phase 1 Single Ascending Dose and Food Effect Studies in Healthy Adults.
Journal: Clinical therapeutics
Published: February 06, 2024
Showing 1-10 of 10
Last Updated: 09/26/2026